MOTS-c is a 16-amino acid peptide encoded in the mitochondrial genome — one of the few known peptides with mitochondrial DNA origin. Discovered in 2015 by researchers at USC, MOTS-c has emerged as a critical regulator of metabolic homeostasis, exercise adaptation, and insulin sensitivity through its activation of AMPK (AMP-activated protein kinase) — the master metabolic switch.
AMPK: The Master Metabolic Regulator
AMPK is activated when cellular energy is low (high AMP:ATP ratio) and responds by switching cells from anabolic to catabolic metabolism: increasing glucose uptake, stimulating fatty acid oxidation, inhibiting fat synthesis, and improving insulin sensitivity. MOTS-c activates AMPK through a pathway that mimics the metabolic effects of exercise — making it sometimes described as an "exercise mimetic."
Insulin Resistance Reversal
MOTS-c improves insulin sensitivity through multiple mechanisms: AMPK activation increases GLUT4 translocation to the cell surface (improving glucose uptake), reduces hepatic glucose production, and decreases ectopic fat accumulation in liver and muscle. In mouse models of diet-induced obesity, MOTS-c treatment reversed insulin resistance and reduced body fat without changes in food intake.
Synergy with GLP-1
MOTS-c and GLP-1 receptor agonists work through completely different mechanisms — GLP-1 primarily reduces food intake through central appetite suppression, while MOTS-c improves peripheral insulin sensitivity and mitochondrial metabolism. The combination addresses both the intake and utilization sides of the metabolic equation, making it a compelling stack for comprehensive metabolic optimization.